However, Cardenas et al. [183] reported that EZH2 inhibition (not expression) promotes EMT in ovarian cancer cells, whereas its expression represses ZEB2, which is a main EMT promoting factor [12]. Here, ZEB2 is linked to ovarian carcinoma.